Abstract
The discovery of ERβ in the middle of the 1990s represents a paradigm shift in our understanding of estrogen signaling. It has turned out that estrogen action is not mediated by one receptor, ERα, but by two balancing factors, ERα and ERβ, which are often antagonistic to one another. Excitingly, ERβ has been shown to be widespread in the body and to be involved in a multitude of physiological and pathophysiological events. This has led to a strong interest of the pharmaceutical industry to target ERβ by drugs against various diseases. In this review, focus is on the role of ERβ in malignant diseases where the anti proliferative activity of ERβ gives hope of new therapeutic approaches.
Original language | English (US) |
---|---|
Pages (from-to) | 63-66 |
Number of pages | 4 |
Journal | Biochemical and Biophysical Research Communications |
Volume | 396 |
Issue number | 1 |
DOIs | |
State | Published - May 21 2010 |
Keywords
- Antiproliferative
- Cancer
- Drug
- Gene expression
- Nuclear receptor
- Pharmaceutical
- Transcription
ASJC Scopus subject areas
- Biochemistry
- Biophysics
- Cell Biology
- Molecular Biology